Development and validation of blood-based predictive biomarkers for response to PD-(L)-1 checkpoint inhibitors: evidence of a universal systemic core of 3D immunogenetic profiling across multiple oncological indications

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was funded by Oxford BioDynamics

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

181 Samples for Oxford Biodynamics for the observational biomarker study Identifying and Developing Chromosomal Conformation Signatures in Patients Undergoing Cancer Immunotherapy were procured from Mount Miriam Cancer Hospital, Penang, Malaysia, a non-for-profit hospital offering specialist treatments for cancer patients. Written ethical approval letters for Oxford Biodynamics were issued by the Medical Research and Ethics Committee (MREC), an independent institute under the Ministry of Health Malaysia. Signed by the Chairman - Dr HJH Salina Abdul Aziz. The lead investigator is Dr Fabian Lee Wei Luen, Mount Miriam Cancer Hospital. The study protocol No 20180201 (NMRR-18-183-40087 (ISR)) is renewed annually, with approved Informed Consent Form. The conduct of the study has been granted approval (via Full Board Review) by the Medical Research & Ethics Committee, Ministry of Health. The Medical Research & Ethics Committee operates in accordance to The International Council for Harmonization of Technical Requirement for Pharmaceutical for Human Use (ICH) and Malaysian Guidelines for Good Practice. Retrospective cohort of 48 samples from NSCLC patients treated with pembrolizumab was commercially procured from Celgene Corporation for development of predictive epigenetic biomarkers for anti-PD-1 therapy (pembrolizumab). Commercial samples were supplied with written approval and confirmation on Jun 7, 2018, by Rafael White, Biospecimen Operations, Global Clinical Research & Development Operations, Celgene Corporation that all subjects for this study signed an informed consent. Oxford Biodynamics Plc, as the public company (London stock Exchange (AIM): OBD) and holder of UK Human Tissue Act (HTA) license #12571, keeps on record evidence for ethical approval for each clinical sample at its UK biomarker processing facility from all third-party suppliers. These records are subject to regular HTA, ISO 13485:2016, ISO 9001:2015 audits.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes